Anivive Lifesciences Inc. has been awarded a $33M contract by the National Institute of Allergy and Infectious Diseases to develop a vaccine against the fungus Coccidiodes, the cause of Valley Fever. The contract aims to utilize Anivive’s animal health Valley Fever vaccine for dogs as a basis for a similar vaccine for humans, with the goal of preventing this serious fungal infection in both humans and animals.
The funding will support activities such as manufacturing, formulation, safety testing, and a Phase 1 clinical trial for humans. Anivive’s Chief Strategy Officer, Dr. Edward Robb, expressed gratitude for the opportunity to accelerate efforts to bring a Valley Fever vaccine to market, potentially becoming the first to prevent this systemic fungal infection.
The timing of this development is crucial, as rising global temperatures and extreme weather conditions contribute to the spread of fungal diseases. The World Health Organization (WHO) has highlighted fungal pathogens as a priority and called for research and policy improvements in this area. Currently, there are no approved antifungal vaccines for human or animal use, making Anivive’s vaccine development efforts all the more significant.
Anivive Lifesciences is a pioneering pet pharmaceutical company that leverages biotech, AI, software, and veterinary medicine to develop new diagnostics, treatments, and preventatives for life-threatening diseases in pets. The company’s pipeline includes innovative technologies for oncology, virology, and infectious diseases. Partnering with organizations like the Valley Fever Center for Excellence and Recipharm, Anivive is poised to deliver groundbreaking solutions for emerging diseases.
Recipharm, a leading Contract Development and Manufacturing Organization in the pharmaceutical industry, and Quigely BioPharma, specializing in product development for infectious diseases and cancer, support Anivive’s vaccine development efforts. Latham BioPharm Group, a life science consulting company, and the University of Arizona Valley Fever Center for Excellence are also key partners in this collaborative endeavor.
With a strong research team and a commitment to advancing vaccine technology, Anivive is at the forefront of combatting fungal infections in both pets and humans. By harnessing the power of innovation and collaboration, Anivive aims to bring a first-in-class vaccine to market and make a meaningful impact on public health. Visit http://www.anivive.com to learn more about Anivive’s mission to protect pets and people from devastating diseases.
Source link
